Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin

2016 ◽  
Vol 18 (7) ◽  
pp. 654-662 ◽  
Author(s):  
D. J. Nunez ◽  
X. Yao ◽  
J. Lin ◽  
A. Walker ◽  
P. Zuo ◽  
...  
2013 ◽  
Vol 56 (12) ◽  
pp. 5094-5114 ◽  
Author(s):  
Yulin Wu ◽  
Christopher J. Aquino ◽  
David J. Cowan ◽  
Don L. Anderson ◽  
Jeff L. Ambroso ◽  
...  

2020 ◽  
Vol 66 (3) ◽  
pp. 185-195
Author(s):  
E.E. Saveleva ◽  
E.S. Tyutrina ◽  
T. Nakanishi ◽  
I. Tamai ◽  
A.B. Salmina

Inhibition of the apical sodium-dependent bile acid transporter (ASBT, also known as IBAT — ileal bile acid transporter, SLC10A2) leads to disruption of the enterohepatic circulation of bile acids and their excretion with fecal masses. This is accompanied by cholesterol utilization for synthesis of new bile acids. ASBT inhibitors are promising drugs for the treatment of such diseases as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes mellitus, necrotic enterocolitis, chronic constipation, atherosclerosis. To date the most known chemically synthesized inhibitors are: A3309, SHP626, A4250, 264W94, GSK2330672, SC-435. All of them are at different stages of clinical trials, which confirm the high efficacy and good tolerance of these inhibitors. Current trends in this field also include directed chemical synthesis of ASBT inhibitors, as well as their search among substances of plant origin.


1997 ◽  
Vol 113 (5) ◽  
pp. 1599-1608 ◽  
Author(s):  
RT Stravitz ◽  
AJ Sanyal ◽  
WM Pandak ◽  
ZR Vlahcevic ◽  
JW Beets ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document